Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns

Figure 7

(a, b) Kaplan–Meier curve of progression-free survival and overall survival for patients with soft tissue sarcoma who used anlotinib as first-line therapy, second-line therapy, or beyond second-line therapy.

(a)

(b)